Browse the evidence

Hepatocyte-specific deletion of MyD88 causes glucose intolerance, hepatic insulin resistance, and inflammation independently of body weight or fat mass gain.

This research highlights that liver-specific immune signaling (MyD88) is crucial for maintaining glucose and lipid balance. While you cannot change your genetics, understanding that liver health is distinct from body weight is key. High-fat diets can unmask or worsen underlying liver metabolic vulnerabilities, even in lean individuals. Focus on liver-supportive lifestyle choices (balanced diet, exercise) to mitigate genetic risks.

Hepatocyte MyD88 regulates bile acid synthesis and profile, which in turn influences gut microbiota composition and host glucose/lipid metabolism.

Your liver produces bile acids that act as hormones, influencing your gut bacteria and how you process sugar and fat. Disruptions in liver signaling (like inflammation) can alter these bile acids, potentially worsening metabolic health. A diet low in excessive fats may help maintain healthier bile acid profiles.

Pharmacologic inhibition of the mTORC1 pathway using rapamycin extends lifespan across multiple species, though its use in humans is limited by side effects like immunosuppression and metabolic dysfunction.

While rapamycin extends lifespan in animals, its side effects make it a poor choice for healthy humans. Instead, focus on lifestyle factors like caloric restriction or exercise, which naturally modulate the mTOR pathway without the severe risks of pharmaceutical inhibition.

Cellular senescence and the senescence-associated secretory phenotype (SASP) contribute to aging and age-related diseases by promoting chronic inflammation and tissue dysfunction.

Senescent cells accumulate with age and contribute to inflammation and tissue dysfunction. Emerging therapies aim to clear these cells (senolytics) to improve healthspan.

Cardiometabolic Syndrome (CMS) is an independent predictor of cardiovascular mortality and morbidity in older adults, with risk increasing as the number of CMS components increases.

Regularly check all components of Cardiometabolic Syndrome (blood pressure, blood sugar, lipids, waist circumference). Managing all of them together is more effective for preventing heart disease and stroke than treating just one.

Women with PCOS have an increased proportion of atherogenic small dense LDL particles and elevated Lipoprotein(a), which are independent risk factors for cardiovascular disease.

Request a complete lipid panel that includes Lipoprotein(a) and ApoB/ApoA-I, not just standard LDL-C. Even if your LDL is normal, elevated Lp(a) and small dense LDL particles common in PCOS increase heart disease risk. Statins may be necessary to address these specific abnormalities.

Thyroid hormones (T4, T3) and insulin concentrations within the normal euthyroid range do not correlate with resting metabolic rate or protein turnover in healthy young adults.

If your thyroid levels are normal, they are not the primary driver of your metabolic rate differences. Focus on body composition rather than trying to 'optimize' normal hormone levels for metabolic boost.

Simultaneous inhibition of MuRF1 and MuRF2 E3 ubiquitin ligases induces synergistic skeletal and cardiac muscle hypertrophy and increases muscle protein synthesis rates.

This research suggests that blocking both MuRF1 and MuRF2 proteins can significantly increase muscle mass and protein synthesis in mice. However, this is a genetic manipulation not currently available or safe for humans, as it also causes severe heart enlargement and early lethality in a large portion of the subjects. It highlights the potential of these proteins as future drug targets for sarcopenia, but current technology does not allow for safe, targeted inhibition in humans.

SGLT2 inhibitors lower blood glucose in Type 2 Diabetes by blocking renal glucose reabsorption, resulting in increased urinary glucose excretion without causing hypoglycemia.

If you have Type 2 Diabetes, SGLT2 inhibitors are a class of medication that helps your kidneys remove excess sugar through urine. This lowers blood sugar and can help with weight loss, without the risk of dangerously low blood sugar (hypoglycemia) common in other treatments. Be aware of a higher risk for urinary or fungal infections.

Metformin reduces fasting plasma glucose by inhibiting hepatic gluconeogenesis via AMPK activation and reducing free fatty acid plasma concentration.

Metformin is the most common first-line medication for Type 2 Diabetes. It works by reducing the amount of sugar your liver makes and improving your body's sensitivity to insulin. Common side effects include stomach discomfort, which often improves over time.

Greater maternal pre-pregnancy BMI is associated with increased offspring fat mass, but this specific maternal effect is small and unlikely to drive the recent obesity epidemic.

Maternal obesity during pregnancy does increase a child's risk of higher fat mass, but the effect is small. It is not the primary driver of the obesity epidemic. Focus on overall family lifestyle and genetics rather than blaming maternal pregnancy weight alone.

Epicardial adipose tissue (EAT) and myocardial steatosis contribute to cardiac dysfunction and atrial fibrillation through lipotoxicity, involving the accumulation of diacylglycerols and ceramides.

Managing overall body fat and metabolic health helps reduce epicardial fat, which may lower the risk of heart rhythm issues and heart failure.

Nonalcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome and a cardiovascular risk factor, driven by lipotoxicity rather than triglycerides alone.

Treating NAFLD requires addressing the underlying metabolic dysfunction and reducing toxic lipid metabolites, not just lowering liver fat content.

Weight loss interventions do not reduce miscarriage rates in overweight and obese women, despite improving pregnancy rates.

While losing weight can help you get pregnant, it does not appear to lower your risk of miscarriage. Focus on the benefits of improved pregnancy rates and overall health rather than expecting weight loss to prevent pregnancy loss.

Long-chain n-3 polyunsaturated fatty acids (omega-3) improve insulin sensitivity and glucose homeostasis in animal models of metabolic syndrome, but have none or marginal effects on metabolic control in human Type 2 diabetes patients.

If you have Type 2 Diabetes, taking omega-3 supplements (EPA/DHA) will likely not improve your blood sugar control or insulin sensitivity, even though it may help lower your triglycerides. Do not rely on omega-3s to manage your glucose levels; continue with prescribed antidiabetic medications and lifestyle changes.

In animal models, omega-3 supplementation prevents the development of insulin resistance and obesity by activating PPARα, AMPK, and reducing endocannabinoid tone, mechanisms that are less effective or absent in humans.

This node explains why animal studies often look better than human trials: mice process omega-3s differently (more peroxisome activation) than humans. This is a mechanistic insight, not a direct human protocol.

Short-term administration of atypical antipsychotics (olanzapine and aripiprazole) induces insulin resistance in healthy subjects independent of weight gain, increased food intake, or psychiatric disease.

If you are prescribed olanzapine or aripiprazole, you may develop insulin resistance even if you do not gain weight or change your diet. This is a direct pharmacological effect on your tissues, not a result of your lifestyle. Monitoring blood sugar and insulin sensitivity is crucial, regardless of your body weight changes.

Olanzapine, but not aripiprazole, causes significant postprandial hyperinsulinemia and elevations in GLP-1 and glucagon, coincident with insulin resistance.

Olanzapine uniquely disrupts your gut-hormone signaling (GLP-1 and glucagon) after eating, leading to high insulin spikes. This is different from other antipsychotics like aripiprazole, which cause insulin resistance without these specific hormonal spikes. This suggests olanzapine has a more complex impact on digestion and metabolism.

Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women by impairing the phosphorylation of protein kinase C-zeta (PKCz) downstream of PI3-kinase, without affecting upstream IRS-1 or mitogenic signaling pathways.

For women with high androgen levels (such as in PCOS), excess testosterone can directly interfere with how fat cells respond to insulin. This happens not by blocking the main insulin signal, but by disrupting a specific downstream step (PKCz) required for glucose uptake. This suggests that managing androgen levels may be crucial for improving insulin sensitivity in these individuals.

Thiazolidinediones (TZDs) improve insulin sensitivity primarily by acting as PPAR-gamma agonists, which promotes adipocyte differentiation and reduces the release of free fatty acids and TNF-alpha from adipose tissue, thereby improving peripheral insulin sensitivity.

If prescribed, TZDs like rosiglitazone or pioglitazone are effective medications for improving insulin sensitivity. They work by changing how fat cells behave, reducing harmful substances that block insulin. Be aware they may cause modest weight gain, but this is often subcutaneous fat, which is less harmful than visceral fat.

Chronic glucocorticoid treatment suppresses brown adipose tissue (BAT) activation in humans, reducing both the volume and glucose uptake of active BAT.

If you are on long-term steroid medication, your body's ability to burn fat via brown fat may be suppressed, potentially contributing to weight gain. This is a known side effect of chronic steroid use, distinct from the acute effects seen in healthy individuals.

Full PPARγ agonists (thiazolidinediones/TZDs) improve insulin sensitivity and induce white fat browning but cause adverse effects including weight gain, visceral obesity, water retention, and increased cardiovascular/bone fracture risk.

Full PPARγ drugs (TZDs) work for blood sugar but often cause weight gain and other health risks. Doctors may prescribe partial agonists or newer drugs to get the blood sugar benefits without the weight gain.

Phosphorylation of PPARγ at Ser273 selectively activates diabetic gene programs (causing insulin resistance) without affecting adipogenic or osteogenic programs, whereas Ser112 phosphorylation promotes osteogenesis.

This is a molecular mechanism. It explains why some diabetes drugs cause insulin resistance despite lowering blood sugar. Researchers are trying to block this specific phosphorylation to make better drugs.

Intermittent rapamycin dosing (once every 5 days) mitigates glucose intolerance and beta-cell dysfunction while maintaining mTORC1 inhibition, compared to daily dosing.

If using rapamycin for longevity, consider an intermittent schedule (e.g., once every 5 days) rather than daily dosing. This approach appears to preserve the anti-aging benefits (mTORC1 inhibition) while significantly reducing the risk of glucose intolerance and beta-cell dysfunction seen with daily use. Consult a physician for dosing protocols.